
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
In vitro skin penetration and drug-release studies are the simplest and most cost-effective methods for characterizing a drug's skin absorption and penetration profiles.
over 23 years ago
Transdermal Drug Formulation and Process Developmentover 23 years ago
Controlled-Release of Oral Dosage Forms





